{"Symbol": "ATRA", "AssetType": "Common Stock", "Name": "Atara Biotherapeutics, Inc", "Description": "Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms Tumor 1; and ATA621 for BK and JCV. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "611 Gateway Boulevard, South San Francisco, CA, United States, 94080", "FullTimeEmployees": "425", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "1008358208", "EBITDA": "-279340992", "PERatio": "None", "PEGRatio": "0", "BookValue": "5.129", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-6.071", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.5427", "ReturnOnEquityTTM": "-0.9826", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-4.984", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "27.44", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "2.5834", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "2.2187", "52WeekHigh": "17.94", "52WeekLow": "4.52", "50DayMovingAverage": "13.1379", "200DayMovingAverage": "11.2818", "SharesOutstanding": "74307904", "SharesFloat": "44552784", "SharesShort": "13558513", "SharesShortPriorMonth": "11718262", "ShortRatio": "21.68", "ShortPercentOutstanding": "0.2", "ShortPercentFloat": "0.2285", "PercentInsiders": "2.456", "PercentInstitutions": "107.985", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}